Pluristem Therapeutics Inc. (Nasdaq: PSTI)
http://www.pluristem.com/
Company Information:
Matam Advanced Technology Park
Building #20
Haifa 31905, Israel
Tel : +972-74-710-7171
Fax : +972-74-710-7172
E-Mail: info@pluristem.com
CIK: 0001158780
Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases.
Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an “off-the-shelf” product.
The company’s GMP-certified in-house manufacturing facilities allow it to efficiently produce commercial quantities of homogeneous, clinical-grade PLX cells. Pluristem is currently the only company manufacturing large quantities of placenta-based cell products using a 3D bioreactor. Driving these development efforts is a management team dedicated to shaping the future of the company and of placenta-based cell therapies. The Pluristem team has many decades of industry and research experience and draws on this as it continues to progress towards company goals.
Management:
http://www.pluristem.com/index.php/about2/management.html
Clinical Program:
http://www.pluristem.com/index.php/clinic-program.html
Recent News and Press:
http://www.pluristem.com/index.php/press-room.html
http://finance.yahoo.com/q/h?s=PSTI+Headlines
http://seekingalpha.com/symbol/PSTI
Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001158780&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
Transfer Agent:
Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
Investor Relations: U.S.A.
Karine Kleinhaus, M.D., M.P.H.
Divisional VP, North-America
karinek@pluristem.com
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp